Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery of orally active chalcones as histone lysine specific demethylase 1 inhibitors for the treatment of leukaemia
Yang Li, Ying Sun, Yang Zhou, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2020) Vol. 36, Iss. 1, pp. 207-217
Open Access | Times Cited: 11

Showing 11 citing articles:

Reversible Lysine Specific Demethylase 1 (LSD1) Inhibitors: A Promising Wrench to Impair LSD1
Xing‐Jie Dai, Ying Liu, Lei-Peng Xue, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 5, pp. 2466-2488
Closed Access | Times Cited: 67
Anticancer Activity of Chalcones and Its Derivatives: Review and In Silico Studies
Fernando Ferreira Leite, Natália Ferreira de Sousa, Bruno Hanrry Melo de Oliveira, et al.
Molecules (2023) Vol. 28, Iss. 10, pp. 4009-4009
Open Access | Times Cited: 25
Annual review of lysine-specific demethylase 1 (LSD1/KDM1A) inhibitors in 2021
Yihui Song, Huiqing Zhang, Xiaoke Yang, et al.
European Journal of Medicinal Chemistry (2021) Vol. 228, pp. 114042-114042
Closed Access | Times Cited: 45
Discovery of novel N-benzylarylamide-dithiocarbamate based derivatives as dual inhibitors of tubulin polymerization and LSD1 that inhibit gastric cancers
Xin-Ying Yuan, Chun-Hong Song, Xiujuan Liu, et al.
European Journal of Medicinal Chemistry (2023) Vol. 252, pp. 115281-115281
Closed Access | Times Cited: 17
Design, Synthesis, and Anticancer Activity Studies of Novel Quinoline-Chalcone Derivatives
Yong-Feng Guan, Xiujuan Liu, Xin-Ying Yuan, et al.
Molecules (2021) Vol. 26, Iss. 16, pp. 4899-4899
Open Access | Times Cited: 28
Recent Progresses in Chalcone Derivatives as Potential Anticancer Agents
Jiahui Yang, Jianmei Lv, Shuxian Cheng, et al.
Anti-Cancer Agents in Medicinal Chemistry (2023) Vol. 23, Iss. 11, pp. 1265-1283
Closed Access | Times Cited: 10
Drug discovery of histone lysine demethylases (KDMs) inhibitors (progress from 2018 to present)
Xingrui He, Hang Zhang, Yingqian Zhang, et al.
European Journal of Medicinal Chemistry (2022) Vol. 231, pp. 114143-114143
Closed Access | Times Cited: 17
LSD1-Based Reversible Inhibitors Virtual Screening and Binding Mechanism Computational Study
Zhili Yin, Shaohui Liu, Xiaoyue Yang, et al.
Molecules (2023) Vol. 28, Iss. 14, pp. 5315-5315
Open Access | Times Cited: 4
Discovery of new potent lysine specific histone demythelase-1 inhibitors (LSD-1) using structure based and ligand based molecular modelling and machine learning
Shada J. Alabed, Malek Zihlif, Mutasem O. Taha
RSC Advances (2022) Vol. 12, Iss. 55, pp. 35873-35895
Open Access | Times Cited: 7
Raloxifene, identified as a novel LSD1 inhibitor, suppresses the migration of renal cell carcinoma
Yuan Ma, Yan Zheng, Yanli Ji, et al.
Future Medicinal Chemistry (2021) Vol. 13, Iss. 6, pp. 533-542
Open Access | Times Cited: 9
A Quinquennial Review of Potent LSD1 Inhibitors Explored for the Treatment of Different Cancers, with Special Focus on SAR Studies
Khursheed Ahmad Sheikh, Ashif Iqubal, Mohammad Mumtaz Alam, et al.
Current Medicinal Chemistry (2023) Vol. 31, Iss. 2, pp. 152-207
Closed Access | Times Cited: 2
Page 1

Scroll to top